martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 18, 2026

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of

View original at finance.yahoo.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of Urban air mobility has long lived somewhere between science fiction and city planning decks…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For Joby, current quarter loss per share expected to widen 5.3% YOY to -$0.20

    80% confidence

  • For Archer current quarter, losses expected to decrease 52.8% YOY to -$0.25 per share

    80% confidence

  • Wall Street analysts recommend caution with consensus Hold rating for Joby Aviation

    80% confidence

  • For Archer fiscal 2026, losses expected to reduce 7.8% annually to -$0.95 per share

    80% confidence

  • Management expects to generate cash, cash equivalents, and short-term investments at the upper end of $500 million to $540 million range for 2025

    80% confidence

  • For Joby fiscal 2026, loss projected to narrow 11.8% to -$0.75 per share

    80% confidence

  • Archer Aviation has consensus Moderate Buy rating overall

    80% confidence

  • Joby plans to produce four aircraft a month by 2027 at Ohio facility

    80% confidence

  • For Joby, full fiscal year losses seen growing 7.6% annually to -$0.85 per share

    80% confidence

  • For Archer current year, losses projected to decline 27.5% YOY to -$1.03 per share

    80% confidence

  • Urban air mobility has long lived somewhere between science fiction and city planning decks

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of — Source | Via News | es.VIA.NEWS